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Abstract
Background: Obesity is known to be related to the development of type 2 diabetes mellitus (T2D). The most com‑
monly used anthropometric indicator (body mass index [BMI]) presents several limitations such as the lack of possibil‑
ity to distinguish adipose tissue distribution. Thus, this study examines the suitability of a body shape index (ABSI) for
prediction of body composition and sarcopenic obesity in obese or overweight T2D subjects.
Methods: Cross-sectional study in 199 overweight/obese T2D adults. Anthropometric (BMI, ABSI) and body composi‑
tion (fat mass [FM], fat-free mass [FFM], fat mass index [FMI] and fat-free mass index, and the ratio FM/FFM as an index
of sarcopenic obesity) data was collected, as well as metabolic parameters (glycated haemoglobin [ HbA1c], mean
blood glucose, fasting plasma glucose [FPG], high-density-lipoprotein cholesterol [HDL], low-density-lipoprotein
cholesterol, total cholesterol, and triglycerides [TG] levels; the ratio TG/HDL was also calculated as a surrogate marker
for insulin resistance).
Results: ABSI was significantly associated with age and waist circumference. It showed a statistically significant corre‑
lation with BMI exclusively in women. Regarding body composition, in men, ABSI was associated with FM (%), while in
women it was associated with both FM and FFM. Both males and females groups with high ABSI scores were signifi‑
cantly older (men: 59.3 ± 10.8 vs 54.6 ± 10.1, p ≤ 0.05; women: 65.1 ± 9.8 vs 58.1 ± 13.3, p ≤ 0.005) and showed lower
FFM values (men: 62.3 ± 9.0 vs 66.2 ± 9.3, p ≤ 0.05; women: 48.7 ± 5.6 vs 54.5 ± 8.9, p ≤ 0.001) compared with low-ABSI
groups. Multiple linear regression revealed that ABSI independently predict FMI and the FM/FFM ratio in women. Sar‑
copenic obesity was identified in 70 (36.5%) individuals according to the FM/FFM ratio. The AUROC of ABSI was 63.1%
(95% CI 54.6–71.6%; p = 0.003) and an ABSI value of 0.083 m11/6 kg−2/3 was the optimal threshold in discriminating
patients with sarcopenic obesity (sensitivity: 48%, specificity: 73%). Moreover, a significant association between ABSI
and FPG was found in men.
Conclusions: ABSI could be useful to identify visceral and sarcopenic obesity in overweight/obese adults with T2D,
adding some relevant clinical information to traditional anthropometric measures.
Keywords: A body shape index, Sarcopenic obesity, Type 2 diabetes, Obesity, Body composition
Background
According to the global trends, the prevalence of diabetes mellitus is expected to increase considerably [1, 2].
Obesity, and especially visceral obesity, is known to be
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related to the development of type 2 diabetes (T2D), and
cardiovascular diseases (CVD) [3, 4], through the release
of fatty acids and inflammatory cytokines into the portal
bloodstream [5].
Some anthropometric measurements considered surrogates for visceral obesity have long been used in medical settings for obesity-associated health risk evaluation.
A commonly used measure is the body mass index (BMI).
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However, it does not serve to distinguish between muscle and fat accumulation and gives no indication of body
shape [6]. An increase in BMI could be attributed to an
increase in either fat mass (FM), fat-free mass (FFM) or
both, limiting the utility of BMI to estimate adiposity [7,
8].
Waist circumference (WC) is widely seen as a measure
of central adiposity. Its association with insulin resistance
has been reported to be better than that of BMI [9–11].
Related indexes, such as waist-height ratio (WHtR),
waist-hip ratio (WHR), and roundness index have been
extensively studied. However, WC and WC-derived
measures (i.e. WHtR) are highly correlated with BMI
[12], limiting, their utility beyond BMI [13]. To overcome
the limitations of the existing anthropometric measures
to efficiently estimate both visceral abdominal and general adiposities and predict mortality.
Krakauer et al. [14] developed a new composite anthropometric measure. A body shape index (ABSI), based on
normalizing WC to BMI and height. The advantage of
ABSI is that it combines information from WC, height
and weight. A high ABSI indicates that WC is higher than
expected for a given height and weight, and corresponds
to a more central concentration of body mass. ABSI predicts mortality independently from BMI [15, 16]. Of note,
the DECODE study group found a positive linear relationship of all-cause CVD mortality with ABSI, whereas
BMI, WC, and WHR showed J-shaped associations [17].
Additionally, ageing is usually associated with an
increase in FM coexisting with a decrease in FFM, leading to sarcopenia [18]. Sarcopenia is characterized by
degenerative loss of skeletal muscle mass and strength
and correlates with physical disability [19]. In the case of
sarcopenic obesity [20], ABSI may be useful, in addition
to the traditional anthropometric measures.
The association of ABSI and body composition measurements has been reported in a geriatric study [21].
Overweight/obese subjects with no significant clinically
comorbidities [22], and Japanese subjects with T2D [23]
have also been studied. The methodology and the results
differed between studies, but overall, they pointed out a
positive relationship between ABSI and visceral and sarcopenic obesity.
Here we assess ABSI in an observational study of
Caucasian obese or overweight subjects with T2D. Our
findings suggest that ABSI is associated with body composition and sarcopenic obesity.

Methods
Design and study subjects

This cross-sectional observational study was carried out
at the Hospital General de Segovia (Segovia, Spain) in
accordance with the Declaration of Helsinki, including
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all amendments, and was approved by the corresponding Independent Research Ethics Committee. All participants provided written informed consent to use their
data.
The study population comprised consecutive Caucasian
overweight/obese (BMI ≥ 25 kg/m2) adult subjects with
T2D. A glomerular filtration rate over 60 ml per minute
per 1.73 m2 of body surface area (modification of diet in
renal disease [MDRD] formula [24]) and normal creatinine levels were used to exclude clinically relevant renal
impairment. Additional criteria for inclusion were not
taking pioglitazone, GLP-1 receptor agonists or SGLT2
inhibitors, and performance of the studies required for
this analysis.
Measurements
Anthropometric parameters

Height (m) and weight (kg) were measured according to
standard methods, and the BMI was then calculated as
weight/height squared (kg/m2). Waist circumference (WC)
was measured at the uppermost border of the iliac crests
in standing positions with a non-stretchable tape (cm).
ABSI was calculated as WC/(BMI2/3 * height1/2), expressed
in m11/6 kg−2/3. Men and women were each divided into
two groups by using the median of individual ABSI measurements as the threshold value. Subjects with ABSI lower
than the median values were assigned to the “lower-ABSI”
group and subjects with greater ABSI than the median
value were assigned to the “higher-ABSI” group.
Body composition measurements

Fat mass (FM) and fat-free mass (FFM) were clinically
determined by bioelectrical impedance analysis and calculated through the software supplied by the manufacturers and expressed in kg [25]. These measurements
were performed in the morning, after an overnight fast.
Subjects were asked to refrain from a strenuous exercise
from the night before and to void the bladder before the
examination. Fat mass index (FMI) and fat-free mass
index (FFMI) were then calculated as FM (kg) and FFM
(kg) divided by the squared height in meters (m2), respectively. The ratio between FM and FFM (FM/FFM) was
calculated as an index of sarcopenic obesity. As per Prado
et al. [26] we used the following cut-off values for FM/
FFM ratio: < 0.40 for metabolic healthy obese individuals in whom the increase in FM relatively low compared
to FFM; FM/FFM ratios between 0.40 and 0.80 for obese
individuals; and FM/FFM > 0.80 for sarcopenic obese
subjects, in whom FM predominates FFM.
Metabolic parameters

The collection of metabolic parameters included glycated
haemoglobin (HbA1c), mean blood glucose (MBG),
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fasting plasma glucose (FPG), high-density lipoprotein
cholesterol (HDL), low-density lipoprotein cholesterol
(LDL), total cholesterol (TC), and triglycerides (TG) levels. The ratio between TG and HDL (TG/HDL) was also
calculated as a surrogate marker for insulin resistance, as
is suggested by Cordero et al. [19].
Statistical considerations

To control for the well-known sexual dimorphism in body
composition, all analyses were stratified by gender. Values
were expressed as mean ± standard deviation (SD) for
quantitative variables and as number and percentages for
categorical variables. The Student’s t test or the Mann–
Whitney U test for quantitative variables and the Fisher’s
exact test or the Chi square test for qualitative variables
were used to compare mean values between groups. Correlation analyses between anthropometric measures and
body composition and metabolic parameters were evaluated with Pearson’s/Spearman correlation analysis. To
determine if ABSI and BMI were independently associated with FM, FFM, FMI, FFMI, FM/FFM ratio, and TG/
HDL index, linear regression analyses were performed.
Correlations between anthropometric parameters and
body composition measurements were adjusted for age,
due to the documented relationship between the ageing
process and changes in body composition, often without
concomitant changes in body weight or BMI [20]. The
area under the ROC curve (AUROC) was determined
to compare the ability of ABSI and BMI to discriminate
between patients with and without sarcopenic obesity.
The significance level was set at p < 0.05 and all statistical analyses were carried out with the statistical package
for the Social Sciences (SPSS) v.22.0 (SPSS, Inc., Chicago,
IL).

Results
Between March 2012 and April 2016, we identified 203
subjects who met the initial selection criteria; of these,
four subjects were excluded due to screening failures
(n = 2) and incomplete data (n = 2). Thus, the evaluable
population comprised 199 subjects (100 women and 99
men), whose characteristics are shown in Table 1.
According to the FM/FFM ratio, 70 (36.5%) subjects
had sarcopenic obesity, as defined by an FM/FFM ratio
> 0.8. Only 9 of the male subjects showed sarcopenic
obesity.
Pearson correlations between different variables are
shown in Table 2 either adjusted or raw values. In both
sexes, WC positively correlated with all body composition
measurements. ABSI was significantly associated with age
(men, r = 0.438, p = 0.000; women, r = 0.220, p = 0.029)
and WC (men, r = 0.577, p = 0.000; women, r = 0.417,
p = 0.000), and achieved a significant association with
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BMI only in women (r = -0.301, p = 0.003). Correlations
between BMI and the body composition parameters
were statistically significant for both men and women
across all measures. Correlations between ABSI and
body composition measurements in men were not significant except for the percentage of FM (r = − 0.302,
p = 0.003), while in women ABSI significantly correlated
with FM (r = − 0.236, p = 0.022) and FFM (r = − 0.270,
p = 0.008). Overall, correlations between BMI and ABSI
with metabolic parameters were not significant for either
men or women (data not tabulated), except for the significant association found between ABSI and FPG in men
(r = − 0.379, p = 0.000), and between BMI and TG in
women (r = − 0.224, p = 0.043).
The ROC curves of ABSI and BMI for predicting sarcopenia are shown in Fig. 1. Additionally, the AUROC of
ABSI is shown in Fig. 1 and had a value of 63.1% (95%
CI 54.6–71.6%; p = 0.003). We estimated a cut-off value
of ABSI with potential clinical utility. In our analysis, the
optimal threshold for the ABSI value in discriminating
patients was 0.083 m11/6 kg−2/3 (sensitivity: 48%, specificity: 73%). For BMI, the cut-off value was 37,45 kg/m2,
with sensitivity of 81% and specificity of 77%.
To selectively analyse the association between ABSI
and anthropometric measures describing adiposity and
sarcopenia independently from BMI, men and women
were divided into two groups by using the median of
individual ABSI measurements as the threshold value
(0.0834 m11/6 kg−2/3). Higher-ABSI men had a mean WC
significantly greater than the lower-ABSI men group
(121.8 ± 13.6 vs 114.9 ± 19.4 cm, p ≤ 0.05). The higherABSI male and female groups were significantly older
(age in years men: 59.3 ± 10.8 vs 54.6 ± 10.1, p ≤ 0.05;
women: 65.1 ± 9.8 vs 58.1 ± 13.3, p ≤ 0.005). With higherABSI vs. lower-ABSI FFM was lower (men: 62.3 ± 9.0 vs
66.2 ± 9.3 kg, p ≤ 0.05; women: 48.7 ± 5.6 vs 54.5 ± 8.9,
p ≤ 0.001), demonstrating the ability of ABSI to identify
sarcopenia. Among women, BMI, FM, FMI, FFM, and
FFMI exhibited significantly greater values in the lowerABSI group than the higher-ABSI group (Table 3).
Multiple linear regression analyses revealed that BMI
independently predicted all body composition parameters both in men and women. ABSI, however, independently predicted FMI and FM/FFM ratio in women
(Additional file 1: Table S1).

Discussion
This study utilizes indexes defining body composition
that are easily obtained in routine clinical practice. It
assesses the relationship between the components of
body composition and abdominal fat surrogate markers
in a retrospective Spanish cohort overweight or obese
adults with T2D.
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Page 4 of 8

Table 1 Baseline characteristics
Men
n = 99
Age (years)
Duration of type 2 diabetes (years)
Height (cm)
Weight (kg)
BMI (kg/m2)
WC (cm)
ABSI (m11/6 kg−2/3)
Body fat (%)
FM (kg)
FFM (kg)
FMI
FFMI
FM/FFM ratio

Women
n = 100

57.0 ± 10.7

61.5 ± 12.2

11.0 ± 6.9

12.9 ± 8.3

167.9 ± 7.2

102.7 ± 20.0

36.4 ± 6.5

118.3 ± 17.0

0.0827 ± 0.0081

36.7 ± 8.9

37.5 ± 15.5

64.5 ± 9.4

< 0.001

39.7 ± 6.9

< 0.001

117.8 ± 14.9

0.0810 ± 0.0072

45.3 ± 5.2

51.4 ± 7.9

18.3 ± 4.8

22.8 ± 2.6

21.5 ± 2.9

0.59 ± 0.26

0.85 ± 0.16

< 0.4, n (%)

11 (11.5)

0 (0.0)

≥ 0.4 and ≤ 0.8, n (%)

76 (79.2)

35 (36.5)

9 (9.4)

61 (63.5)

> 0.8, n (%)

HbA1c (%)
MBG (mg/dL)
FPG (mg/dL)
HDL (mg/dL)
LDL (mg/dL)
TG (mg/dl)
TC (mg/dL)
TG/HDL

8.4 ± 1.3

194.8 ± 38.5

182.0 ± 50.2

38.8 ± 11.7

99.8 ± 30.2

202.7 ± 225.1

176.1 ± 35.0

6.3 ± 9.5

8.3 ± 1.7

190.5 ± 48.9

172.1 ± 73.0

44.8 ± 8.9

112.6 ± 40.6

199.9 ± 182.6

194.7 ± 57.7

4.7 ± 5.1

≤ 1.8, n (%)

7 (9.5)

7 (10.1)

> 1.8, n (%)

67 (90.5)

62 (89.9)

Creatinine (mg/dL)

1.0 ± 0.2

0.8 ± 0.2

Glomerular filtration rate (mL/min/1.73 m2)a

91.5 ± 20.8

0.004
0.247

154.8 ± 7.0

95.1 ± 19.3

44.0 ± 12.7

13.3 ± 5.5

p value

79.8 ± 18.9

0.007
0.791
0.001
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001

0.109
0.033
0.109
< 0.001
0.060
0.246
0.003
0.440
> 0.999
< 0.001
< 0.001

Data are expressed as mean ± standard deviation, unless otherwise indicated

ABSI A body shape index, BMI body mass index, FM fat mass, FFM free-fat mass, FMI fat mass index, FFMI free-fat mass index, FM/FFM ratio fat mass-free-fat mass, FPG
fasting plasma glucose, HbA1c haemoglobin A1c, HDL high-density lipoprotein cholesterol, LDL low-density lipoprotein cholesterol, MBG mean blood glucose, TC total
cholesterol, TG Triglycerides, WC Waist circumference
a

MDRD formula [25]

In our series, we found that BMI was highly and positively correlated with all parameters of body composition (i.e. FM, FFM, FMI, etc.), in both males and females.
The observed lack of correlation between ABSI and BMI
in the general population was confirmed in the male
cohort, while there was a modest correlation in the
female cohort. This is in line with the recent study conducted by Hardy et al. [27] that aimed to determine the
best anthropometric discriminators of T2D among white
and black subjects in a large cohort. It was concluded
that those anthropometric measures that included WC

(such as WHR) were the strongest discriminators of T2D
across race-gender groups, while BMI was a comparable discriminator to WC among males, but not in female
subjects.
ABSI was positively correlated with WC both in males
and females. A higher ABSI-value is an indication of a
higher abdominal fat deposition [14] that leads to systemic inflammation [28], insulin resistance [29], and
accompanies a systemic loss of skeletal muscle mass, as
reported previously [30]. In our study, the association
of ABSI with body composition parameters differed by

Gomez‑Peralta et al. Diabetol Metab Syndr (2018) 10:21
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Table 2 Pearson’s rank correlation for body mass compositions measurements in men and women
WC

% FM

BMI

Age

0.260f

0.693a

ABSI

FM

FFM

FMI

FFMI

FM/FFM

Men
WC
% FM
BMI

1
g

0.322

a

0.730

a

1

0.697
a

0.691

1

Age

–

–

–

0.580a

FM

0.895a

− 0.302d

− 0.107

a

FFM

0.406

FMI

0.869a
a

FFMI

0.495

FM/FFM

0.711a

− 0.164
0.924a

g

− 0.313

− 0.156

ABSI

0.888a

0.136

1

0.883a

–
–

a

0.374

–

0.906a

–

a

0.573

–

0.938a

0.729a

–

0.548a

0.722a

− 0.017

− 0.049

0.577a

0.833a

a

a

− 0.395

− 0.164

a

0.438

1
− 0.030
− 0.110

0.892

a

0.885

h

− 0.225

− 0.124

% FM
BMI

1
a

0.551

a

0.723

a

1

0.631
a

0.628

1

− 0.087

Age

–

–

–

ABSI

0.431a

FM

0.847a

− 0.091

− 0.291r

a

− 0.123
1

0.812a

0.863a

d

a

–
–

FFM

0.590

0.303

0.750

–

FMI

0.852a

0.820a

0.906a

–

FFMI

0.556a

0.224q

0.795a

–

FM/FFM

0.699a

0.944a

0.677a

–

a

0.916

0.389

0.908

− 0.153

− 0.162

a

0.211i

1

0.827a

− 0.106

− 0.164

a

0.499a
− 0.069

a

0.553

0.071

− 0.092

0.975a

0.668a
0.932a
0.736a
− 0.179

− 0.023

0.175
a

− 0.061

0.923a

0.184

1

0.081

0.794

− 0.023

0.976a

0.058

1

0.173

0.020

0.921a

0.417a

0.827a

0.571a

0.849a

0.556a

0.696a

a

b

a

h

0.945a

a

0.680a

− 0.060

0.196

0.816

Women
WC

0.376a

− 0.115

d

− 0.301

k

0.220

1
− 0.194

s

0.812

a

0.856

− 0.236

l

− 0.236n
1

a

a

− 0.190

0.323

a

0.742

m

− 0.280

− 0.270j

0.764a

0.188
0.944a

0.822

a

0.945a

1
− 0.124

0.225

0.907

0.794

− 0.110

− 0.029

− 0.182

0.944a
a

-0.158
− 0.135
1

− 0.110

− 0.196

0.582a
a

0.794

− 0.097

0.856a
0.335b

− 0.222

0.748

1

0.657

− 0.163

0.950a

0.656a

1

0.684a

0.869a

− 0.194

0.593a

0.819a

0.685a

1

0.243o

− 0.075

0.859a

0.318g

0.867a

0.241t

1

The upper-right triangle of the table shows correlations of the raw values, while the lower-left triangle shows correlations adjusted for age
ap = 0.000; bp = 0.001; cp = 0.016; dp = 0.003; ep = 0.010; fp = 0.011; gp = 0.002; hp = 0.028; ip = 0.039; jp = 0.008; kp = 0.029; lp = 0.021; mp = 0.005; np = 0.022;
op = 0.017; pp = 0.007; qp = 0.030; rp = 0.004; sp = 0.031; tp = 0.041

ABSI A body shape index, BMI body mass index, % FM Percentage of fat mass, FM fat mass, FMI fat mass index, FFM Fat-free mass, FFMI Fat-free mass index, FM/FFM
ratio between fat mass and fat-free mass, WC waist circumference

gender: ABSI was negatively associated with the percentage of FM (p = 0.000) in the male cohort, while it was
negatively associated with both FM (p = 0.022) and FFM
(p = 0.008) in the female cohort. This discrepancy in the
findings between men and women could be explained
by the differences in body fat distribution [31]. In men,
adipose tissue tends to be more centrally deposited, suggesting that WC would be sensitive to FM, whereas in
women adipose tissue is mainly deposited in the lower
body (gluteal-femoral), indicating that WC may be less
sensitive to FM [32].
The higher-ABSI females and males showed significantly lower FFM than the lower-ABSI groups, with comparable BMI in men and lower BMI in women. These
findings could support the hypothesis that abdominal
fat deposition may be associated with a loss of skeletal

muscle mass in some subjects, i.e. sarcopenic obesity.
Obesity-related sarcopenia, is a syndrome of progressive
and generalised loss of skeletal muscle mass and function,
characterized by a higher FM in relation to FFM [26].
Our study indicates that ABSI may not be just a marker
of visceral obesity, but may also represent an index of
decreased muscle mass (i.e. sarcopenia) in T2D subjects,
which is congruent with the positive correlation of ABSI
and age generally reported and also found in our sample.
The AUROC analysis supports that ABSI showed ability for predicting the presence of sarcopenic obesity (the
lower bound of the 95% CI of AUC is greater than 0.5;
[33]). Even though the ability of BMI to discriminate
between patients with and without sarcopenic obesity is
higher than for ABSI, as indicated by the respective sensitivity and specificity values, ABSI could add relevant

Gomez‑Peralta et al. Diabetol Metab Syndr (2018) 10:21
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AUC

1,0

BMI
ABSI
Reference
line

0,8

Sensitivity

0,6

0,4

0,2

0,0

0,0

0,2

0,4

0,6

0,8

1,0

1 - Specificity
Fig. 1 ROC curve for ABSI to discriminate between patients with and without sarcopenic obesity

information about abdominal obesity, body composition
and mortality risk. In fact, our proposed ABSI cut-off
point diagnostic of sarcopenic obesity (0.083 m11/6 kg−2/3)
exactly agreed with the finding of a previous study [14],
where ABSI above the same threshold predicted a higher
mortality relative hazard.
The data presented add to the emerging, growing body
of literature regarding different aspects of ABSI. A recent
longitudinal study conducted with Australian adults
showed a positive association between ABSI and mortality, suggesting that this measure could be a useful predictor of mortality hazard in different populations [34].
In this context, further studies are needed to investigate

whether ABSI could be used as an indicator of the effectiveness of lifestyle modifications in T2D subjects.
The authors recognise some limitations in the study
that should be considered when interpreting the results.
First of all, this is an observational study with a crosssectional design; therefore, there is no patient follow-up,
which would be of importance to elucidate the correlation between body composition and ABSI; besides, we
cannot rule out that some degree of bias may have been
introduced. Secondly, as this study was performed at a
single centre, findings in other centres may be different
and, certainly, further confirmation is needed. Nonetheless, all these findings should guide further prospective
studies with some broader samples [34].
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Table 3 Body and metabolic parameters
and female subjects with lower- or higher-ABSI
Men

Age
BMI
WC
% of FM
FM
FFM
FMI
FFMI
FM/FFM
HbA1c
HDL
LDL
TG
TC
TG/HDL
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in

male

Women

Lower-ABSI

Higher-ABSI

Lower-ABSI

Higher-ABSI

54.6 ± 10.1

59.3 ± 10.8a

58.1 ± 13.3

65.1 ± 9.8b

a

116.1 ± 16.5

119.5 ± 13.1

37.1 ± 7.3

35.7 ± 5.9

114.9 ± 19.4

121.8 ± 13.6

39.6 ± 17.8

35.5 ± 13.3

37.8 ± 10.2

35.8 ± 7.5

42.0 ± 7.1

45.9 ± 5.3

47.6 ± 13.3

37.4 ± 6.1c
44.7 ± 5.2

41.0 ± 11.6a

66.2 ± 9.3

62.3 ± 9.0a

54.5 ± 8.9

48.7 ± 5.6c

22.9 ± 2.5

22.6 ± 2.8

22.5 ± 3.0

20.6 ± 2.4c

13.9 ± 6.4
0.60 ± 0.30
8.3 ± 1.3

37.9 ± 10.8

93.4 ± 29.1

201.5 ± 200.8

170.4 ± 32.8
6.1 ± 8.0

12.9 ± 4.6

19.6 ± 4.8

0.58 ± 0.24

0.87 ± 0.16

8.6 ± 1.4

39.9 ± 12.7

107.2 ± 30.9

202.2 ± 253.8

182.5 ± 36.7

6.6 ± 11.0

8.1 ± 1.7

43.2 ± 8.6

106.0 ± 39.0

161.8 ± 79.5

179.4 ± 37.3
4.1 ± 2.4

17.2 ± 4.6a
0.83 ± 0.16
8.3 ± 1.6

46.1 ± 8.9

119.8 ± 42.3

244.3 ± 250.8

212.3 ± 71.6b
5.4 ± 7.0

Data are expressed as mean ± standard deviation

BMI body mass index, % FM Percentage of fat mass, FM fat mass, FMI fat mass
index, FFM Fat-free mass, FFMI Fat-free mass index, FM/FFM ratio between fat
mass and fat-free mass, HDL High-density lipoprotein cholesterol, LDL Lowdensity lipoprotein cholesterol, TG Triglycerides, TC Total cholesterol, WC waist
circumference
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